PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Liraglutide
CUT · IV

Liraglutide

The daily ascent. Older, faster on / off.

From / per milligram
$24$—/mg · 3MG
Sizes available
—
Lab certificate (COA)
Arrives with shipment
View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

FDA-approved weight-loss and type 2 diabetes therapy (Saxenda / Victoza). First-generation GLP-1 obesity drug.

Mechanism · GLP-1 receptor agonist. First-generation. FDA approved 2010 (T2DM) / 2014 (obesity).

Who

Best for. Not for.

Best for

  • Pediatric obesity (12+). Saxenda FDA approval (2020).
  • Anyone who prefers (or requires) a daily protocol over a weekly one.
  • Type 2 diabetes (Victoza 2010 FDA approval).
  • Longest long-term safety record in the class (15+ years).

Not for

  • Personal or family history of MTC or MEN-2 (FDA boxed warning).
  • History of pancreatitis.
  • Pregnancy or nursing.
  • Type 1 diabetes or elevated DKA risk.
What it does

Mechanism, dose, ramp, risk.

Mechanism
GLP-1 receptor agonist. Daily dosing alternative to Semaglutide.Source · PEPVERA editorial
Target dose
1.8 mg / day by week 5.Source · PEPVERA editorial
Ramp
5 weeks. Daily injection.Source · PEPVERA editorial
Risks
Same family as Semaglutide. Daily injection burden.Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Liraglutide

FDA-approved weight-loss and type 2 diabetes therapy (Saxenda / Victoza). First-generation GLP-1 obesity drug.

Pros

  • · FDA pediatric (12+) approval (Saxenda 2020).
  • · Longest safety record in the GLP-1 class.
  • · Daily titration flexibility unavailable on weekly agents.

Cons

  • · Daily injection burden vs weekly semaglutide or tirzepatide.
  • · Lower efficacy: ~8% mean weight loss vs ~15% (semaglutide) or ~21% (tirzepatide).

Semaglutide

Weekly injection. Deeper weight loss (~15% vs ~8%).

Pros

  • · Once-weekly convenience.
  • · Stronger efficacy.

Cons

  • · No pediatric approval.
  • · Daily titration not possible.

See Semaglutide →

Tirzepatide

Weekly + GIP. Best-in-class fat loss (~21%).

Pros

  • · Best-in-class efficacy.

Cons

  • · Higher cost.
  • · No pediatric approval.

See Tirzepatide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicGLP-1research-only
Suppliers

Compare 0 suppliers

No verified suppliers yet for this compound.

❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Same family as Semaglutide. Daily injection burden. These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

5 weeks. Daily injection.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

1.8 mg / day by week 5.

Terminus

Reconstitution

Draw 20 units.

0.3 mg = 0.20 mL at 1.50 mg/mL. 10.0 doses per vial.

cut · IV

Liraglutide · 3mg